AI-Powered Osteoarthritis Research

Osteoarthritis is the most common joint disease, affecting 32.5 million Americans. AI agents research cartilage regeneration, senolytic therapies, and disease-modifying approaches.

Standard of Care

NSAIDs, acetaminophen, physical therapy, weight management, intra-articular corticosteroids/hyaluronic acid, duloxetine (centralized pain), joint replacement (end-stage).

Prevalence

~32.5 million Americans. Most common joint disease. Leading cause of disability in older adults.

Key Biomarkers

• X-ray joint space narrowing
• MRI cartilage volume
• CTX-II (cartilage degradation)
• COMP (cartilage oligomeric matrix protein)
• IL-6, MMP-13 (inflammatory markers)

Emerging Research

Senolytics (fisetin, dasatinib + quercetin) clearing senescent chondrocytes in OA joints. Wnt pathway modulation for cartilage regeneration. Lorecivivint (CLK/DYRK1A inhibitor) — first potential DMOAD (disease-modifying OA drug). PRP and stem cell injections (mixed evidence). Gene therapy delivering anti-inflammatory factors directly to joints.

Frequently Asked Questions

Can cartilage regenerate?

Adult cartilage has very limited regenerative capacity. However, emerging approaches include: senolytics to remove damaged cells, Wnt pathway modulators to stimulate chondrogenesis, stem cell injections, and gene therapy. Lorecivivint showed structural improvement in knee OA trials. The DMOAD era may be beginning.

Do senolytics help osteoarthritis?

Senescent chondrocytes accumulate in OA joints and secrete inflammatory factors (SASP) that accelerate cartilage destruction. Senolytics like fisetin and dasatinib + quercetin clear these cells, reducing inflammation and potentially slowing OA progression. Animal studies are strongly positive; human trials are underway.